Read the story behind the quarter.
Income statement, balance sheet, and cash flow—connected to the customer situation, marketing choices, operating indicators, and real competitive alternatives.
Five reports to start with
Medtronic FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Medtronic reported $36.4B in revenue and $6.5B in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2026 · STESTERIS FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
STERIS reported $5.9B in revenue and $1.1B in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2026 · CRVLCorVel FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
CorVel reported $959M in revenue and $110M in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2026 · HAEHaemonetics FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Haemonetics reported $1.3B in revenue and $157M in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2026 · DOCSDoximity FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Doximity reported $645M in revenue and $215M in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →121 earnings analyses
Primary sources · US GAAP · USD millions
AtriCure FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
AtriCure reported $535M in revenue and -$9M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · ICUIICU Medical FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
ICU Medical reported $2.2B in revenue and $43M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · CYHCommunity Health Systems FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Community Health Systems reported $12.5B in revenue and $1.5B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · PODDInsulet FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Insulet reported $2.7B in revenue and $474M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · CRLCharles River Laboratories FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Charles River Laboratories reported $4B in revenue and $25M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · RAREUltragenyx Pharmaceutical FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Ultragenyx Pharmaceutical reported $673M in revenue and -$535M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · CNCCentene FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Centene reported $194.8B in revenue and -$7.6B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · BSXBoston Scientific FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Boston Scientific reported $20.1B in revenue and $3.6B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · IQVIQVIA FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
IQVIA reported $16.3B in revenue and $2.2B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · HALOHalozyme Therapeutics FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Halozyme Therapeutics reported $1.4B in revenue and $469M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · AMGNAmgen FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Amgen reported $36.8B in revenue and $9.1B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · VRTXVertex Pharmaceuticals FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Vertex Pharmaceuticals reported $12B in revenue and $4.2B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · INSPInspire Medical Systems FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Inspire Medical Systems reported $912M in revenue and $51M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · OMOutset Medical FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Outset Medical reported $119M in revenue and -$67M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · BIOBio-Rad Laboratories FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Bio-Rad Laboratories reported $2.6B in revenue and $47M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · LLYEli Lilly FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Eli Lilly reported $65.2B in revenue and $25.7B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · DXCMDexcom FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Dexcom reported $4.7B in revenue and $912M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · ZTSZoetis FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Zoetis reported $9.5B in revenue and $3.4B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · BAXBaxter International FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Baxter International reported $11.2B in revenue and -$957M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · ALNYAlnylam Pharmaceuticals FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Alnylam Pharmaceuticals reported $3.7B in revenue and $502M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · ILMNIllumina FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Illumina reported $4.3B in revenue and $807M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · NVSTEnvista Holdings FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Envista Holdings reported $2.7B in revenue and $216M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · JNJJohnson & Johnson FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Johnson & Johnson reported $94.2B in revenue and $26.8B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · BMYBristol Myers Squibb FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Bristol Myers Squibb reported $48.2B in revenue and $7.1B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →
